PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals — Investor Presentation (November 2019)

31 slides from PhaseBio Pharmaceuticals's investor presentation, Nov 14, 2019

  1. Slide 1: Corporate Overview Fourth Quarter 2019

    Corporate Overview Fourth Quarter 2019 Exhibit 99.2

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”)

  3. Slide 3: Company Overview

    Company Overview Therapeutic Focus Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications Product Candidates PB2452 – Novel agent for immediate and sustained reversal of ticag

  4. Slide 4: A Clinical Stage, Orphan Disease-Focused Biopharmaceutical Company

    Program Indication/Therapeutic Area Pre-Clinical Phase 1 Phase 2 Phase 3 WW Commercial Rights Milestones PB2452 Reversal of Ticagrelor Antiplatelet Activity Q1 2020: Initiate Phase 3 trial based on plan to pursue accelerated regulatory pathway PB1046 Pulmonary Arterial Hypertension (PAH) 2H 2020: Re

  5. Slide 5: Corporate

    Corporate

  6. Slide 6: Recent Corporate Highlights

    Recent Corporate Highlights Initiated PB2452 Phase 2b trial: October 2019 Phase 2b trial initiation marked the beginning of FDA-aligned registrational trials to support the submission of a BLA for potential accelerated approval of PB2452 Completed PB2452 Phase 2a trial: September 2019 Observed effic

  7. Slide 7: Third-Quarter 2019 Financial Highlights

    Third-Quarter 2019 Financial Highlights Operating expense: $11.8M R&D: $9.0M SG&A: $2.8M Loss from Operations: ($11.6M) Net Loss of ($11.4M) or ($0.40) per share 28.7M shares used for computing Q3 2019 net loss per share Cash and cash equivalents as of 09/30/2019: $81.8M All values in USD millions e

  8. Slide 8: Experienced Management Team

    Experienced Management Team JONATHAN MOW Chief Executive Officer Amylin Pharmaceuticals, Corus Pharma, PathoGenesis, BMS SUSAN ARNOLD, PhD VP of Preclinical & CMC Targeted Genetics, Viromed Biosafety Labs, BioRexis, NuPathe JIM BALLANCE, PhD VP Research & Scientific Affairs Delta Biotechnology, Aven

  9. Slide 9: PB2452 – Reversal Agent for Ticagrelor

    PB2452 – Reversal Agent for Ticagrelor

  10. Slide 10: PB2452 - Novel reversal agent for Brilinta (ticagrelor)

    PB2452 - Novel reversal agent for Brilinta (ticagrelor) Human monoclonal antibody fragment (Fab), delivered intravenously in the hospital Phase 2b trial ongoing in older and elderly subjects Pivotal Phase 3 trial planned to initiate in Q1 2020 Phase 1 trial published in the New England Journal of Me

  11. Slide 11: PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor

    PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor ADP ADP Platelet ADP binds to P2Y12 receptor causing platelet aggregation Ticagrelor binds to P2Y12, inhibiting ADP-induced platelet aggregation This is a reversible process with ticagrelor cycling on/off the P2Y12 receptors PB2452:ticag

  12. Slide 12: Positive Preliminary PB2452 Phase 2a Results

    Positive Preliminary PB2452 Phase 2a Results In September 2019, positive preliminary results from the PB2452 Phase 2a trial were disclosed via press release1 This was the first trial of PB2452 to include older (ages 50-64) and elderly (ages 65-80) subjects on dual antiplatelet therapy of ticagrelor

  13. Slide 13: Accelerated Approval pathway for PB2452

    FDA agreed that Accelerated Approval pathway is the appropriate regulatory pathway for PB2452 Single, non-randomized, open-label Phase 3 trial in both surgical and major bleeding populations planned to support a Biologics License Application (BLA) BLA submission for Accelerated Approval to include d

  14. Slide 14: PB2452 Granted Breakthrough Therapy Designation

    PB2452 Granted Breakthrough Therapy Designation In April 2019, PB2452 was granted Breakthrough Therapy designation by FDA Designation supported by Phase 1 trial results, which were published in the New England Journal of Medicine1 Breakthrough Therapy designation may be granted by FDA when prelimina

  15. Slide 15: PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects

    PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects Randomized, double-blind, placebo-controlled, single ascending dose (SAD), sequential group study (n=64) 3:1 randomization, PB2452-Placebo Higher-dose cohorts pre-treated with ticagrelor After 48 hours of ticagrelor, platelet aggregation was

  16. Slide 16: Normalized Platelet Function After Ticagrelor Reversal

    PRU= Platelet Reactivity Units Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J Med 2019;Mar 17:[Epub ahead of print]. Presented by Dr. Deepak L. Bhatt at the American College of Cardiology Annual Scientific Session (ACC 2019), New Orlea

  17. Slide 17: Treatment-Emergent Adverse Events in Phase 1 Trial

    Treatment-Emergent Adverse Events in Phase 1 Trial Preferred Term All Placebo (N=16) n (%) All PB2452 (N=48) n (%) Total Number of TEAEs 3 27 Number of volunteers with at Least 1 TEAE 2 (12.5) 17 (35.4) Infusion site bruising 0 4 (8.3) Medical device site reaction 0 3 (6.3) Infusion site extravasati

  18. Slide 18: Clinical Trial Timelines

    Clinical Studies BLA enabling data Clinical Trial Timelines Phase 2a tested additional reversal regimen to cover 180 mg BID (2x recommended dose) in healthy subjects Trial completed in Q3 2019 Phase 2b initiated in October 2019, N=200 total, evaluation of dosing regimen and overall safety of PB2452

  19. Slide 19: Continued Long Term Unit Growth of Ticagrelor Fueled by PB2452 Approval

    Continued Long Term Unit Growth of Ticagrelor Fueled by PB2452 approval Brilinta/Brilique sales in 2018 were $1.32B and growing (+22% Y/Y) Patient growth drives Y/Y revenue growth in all regions: EU (+18%), US (+16%), Emerging Markets (+46%) In February 2019, Brilinta Phase III THEMIS1 trial met pri

  20. Slide 20: PB2452 Program Summary and Next Steps

    PB2452 Program Summary and Next Steps Product profile: Immediate, complete and sustained reversal of ticagrelor antiplatelet effects Major bleeding and urgent surgical scenarios require immediate and sustained reversal Duration of reversal dependent on PB2452 infusion length Clinically important, im

  21. Slide 21: Elastin-Like Polypeptide Technology (ELP) – Engine for Growth

    Elastin-Like Polypeptide Technology (ELP) – Engine for Growth

  22. Slide 22: Prolonged Circulating Half-Life with ELP Technology

    PROLONGED CIRCULATING HALF-LIFE Repeating Sequence of Human Elastin Peptides VPGXG Peptide/Protein (VIP, GLP1, etc.) Active Moiety “Biopolymer” n UP TO 200x INCREASE IN ½ LIFE Proprietary Elastin-Like Polypeptide (ELP) Technology Growth Engine for PhaseBio Preclinical Pipeline ↑ Temperature COACERVA

  23. Slide 23: ELP: A Highly Flexible Technology for Modulating Pharmacokinetics

    ELP: A Highly Flexible Technology for Modulating Pharmacokinetics VERSATILE: MANY ACTIVE MOIETIES POSSIBLE Peptides or proteins can be genetically fused to N- or C-terminus1, or both. Chemical conjugation to small molecules or peptides LOW COST MANUFACTURING Can be produced in E.coli, yeast or mamma

  24. Slide 24: PB1046 - Once Weekly VIP Analog for Pulmonary Arterial Hypertension

    PB1046 - Once Weekly Vasoactive Intestinal Peptide (VIP) Analog for Pulmonary Arterial Hypertension

  25. Slide 25: High Unmet Need in an Orphan Disease

    High Unmet Need in an Orphan Disease Primary Pulmonary Arterial Hypertension (PAH, WHO Group 1 PH) High unmet need for novel disease-modifying PAH therapies for greater efficacy All 3 approved drug classes in PAH are vasodilators: prostacyclin, endothelin, and nitric oxide pathways Patients inevitab

  26. Slide 26: PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug

    PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug PRECLINICAL STUDIES Support Clinical Development for: Pulmonary Arterial Hypertension DMD Cardiomyopathy Heart Failure (Chemotherapy-Induced HF or HFpEF) Cystic Fibrosis MECHANISM OF ACTION VIA VPAC2 RECEPTOR Potent vasodilator Anti-inflamm

  27. Slide 27: PHASE 1 Studies Completed

    PHASE 1 Studies Completed PAH PHASE 2 Studies Well tolerated for a week over broad range of exposure; no drug-related SAEs Prolonged PK/PD profile over 1 week VIP activity confirmed (Systolic and Diastolic BP lowering) Well tolerated across dose range; no drug-related SAEs Replicated PK/PD from SAD

  28. Slide 28: PB1046 Single Ascending Dose Study

    PB1046 Single Ascending Dose Study PK and PD Support Once-Weekly SC Administration Single subcutaneous injections in hypertensive patients washed off medications Well tolerated, week-long PK, dose-dependent VIP activity observed Supports weekly SC dosing in multi-dose studies Serum Concentration PB1

  29. Slide 29: PB1046 Multiple Ascending Dose Study

    PB1046 Multiple Ascending Dose Study Multi-Dose Safety and PK/PD Confirmed in HFrEF Patients MAD in HFrEF completed 4Q2017 Weekly SC injections x 4 weeks in 29 HF patients maintained on SOC meds Well tolerated in a sick patient population on multiple vasoactive medications Prolonged PK profile repli

  30. Slide 30: PB1046 Phase 2b PAH Study Actively Recruiting

    PB1046 Phase 2b PAH Study Actively Recruiting PAH WHO functional class II/III subjects on two drug oral SOC therapy 16 week randomized, double-blinded, controlled study with extension Primary endpoints: Pulmonary vascular resistance (PVR) via RHC, 6MWD, safety Designed to support placebo-controlled

  31. Slide 31: Slide 31

PhaseBio Pharmaceuticals — Investor Presentation (November 2019) on 6ix